Related Experiment Video
Updated: Aug 24, 2025

Investigation of Genetic Dependencies Using CRISPR-Cas9-based Competition Assays
Published on: January 7, 2019
A Molecular Switch between Mammalian MLL Complexes Dictates Response to Menin-MLL Inhibition
Yadira M Soto-Feliciano1, Francisco J Sánchez-Rivera2, Florian Perner3,4,5
1Laboratory of Chromatin Biology and Epigenetics, The Rockefeller University, New York, New York.
Menin-MLL inhibitors disrupt leukemia survival by altering chromatin modifiers. Reactivating tumor suppressor genes with CDK4/6 inhibitors overcomes resistance to these leukemia treatments.
Area of Science:
- Epigenetics and Cancer Biology
- Molecular Oncology
- Chromatin Regulation
Background:
- Menin protein interacts with MLL1-fusion proteins, a target for leukemia treatment.
- Small molecule inhibitors targeting Menin-MLL interactions are in clinical trials for leukemia.
- Understanding resistance mechanisms to Menin-MLL inhibitors is crucial for effective leukemia therapy.
Purpose of the Study:
- To investigate the molecular mechanisms dictating response to Menin-MLL inhibitors in leukemia.
- To identify novel therapeutic strategies to overcome resistance to Menin-MLL inhibitors.
- To elucidate the role of chromatin-modifying complexes in leukemia survival and treatment response.
Main Methods:
- Integration of chromatin-focused and genome-wide CRISPR screens.
- Application of genetic, pharmacologic, and biochemical approaches.
- Utilized murine and human leukemia models.
Main Results:
- Discovered a molecular switch between MLL1-Menin and MLL3/4-UTX complexes that governs response to Menin-MLL inhibitors.
- MLL1-Menin complex impedes MLL3/4-UTX binding, maintaining leukemia cell survival.
- Disruption of Menin-MLL1 interaction activates a tumor-suppressive program via UTX, dictating therapeutic response.
- CDK4/6 inhibitors reactivate repressed tumor suppressor genes, mitigating resistance to Menin inhibitors in leukemia.
Conclusions:
- Menin-MLL and MLL3/4-UTX complexes play conserved roles in epigenetic regulation and leukemia.
- Therapeutic reactivation of tumor suppressor gene programs offers a strategy to overcome Menin inhibitor resistance.
- Findings provide insights into targeting epigenetic pathways for improved leukemia treatment outcomes in clinical trials.
Related Concept Videos
Abnormal Proliferation
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Hedgehog Signaling Pathway
Master Transcription Regulators

